Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Robin Young, CEO, Amur Minerals #AMC talks long-term strategy


Int.biotech. Share Price (IBT)



Share Price Information for Int.biotech. (IBT)


Share Price: 596.00Bid: 588.00Ask: 598.00Change: 0.00 (0.00%)No Movement on Int.biotech.
Spread: 10.00Spread as %: 1.70%Open: 596.00High: 598.00Low: 586.00Yesterday’s Close: 596.00

International Biotechnology Trust Plc Ord 25P

Int.biotech. is listed in the FTSE All-Share, FTSE Small Cap
Int.biotech. is part of the Investment Companies sector






Share Price SpacerPrice
596.00
Share Price SpacerBid
588.00
Share Price SpacerAsk
598.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
60,201
Share Price SpacerOpen
596.00
Share Price SpacerHigh
598.00
Share Price SpacerLow
586.00
Share Price SpacerClose
596.00
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 37.55m £223.78m 500

52 Week High 650.00 52 Week High Date 9-OCT-2017
52 Week Low 518.00 52 Week Low Date 4-APR-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
35 17,500 36,501 4.946 120.51 11.50 1.93


London South East Users info for Int.biotech.




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

25-May-18
16:35:23
596.00
926
Buy* 
588.00
598.00
5,519
Trade Type:
Ordinary

25-May-18
16:35:19
596.00
1,204
Buy* 
586.00
596.00
7,176
UT 
Trade Type:
Uncrossing Trade

25-May-18
16:27:07
596.00
137
Buy* 
590.00
596.00
816.52
Trade Type:
Automatic execution




View more Int.biotech. trades >>

Directors Deals for Int.biotech. (IBT)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Feb-16Buy
Trade Notifier Information for International Biotech Trust
Jim Horsburgh held the position of Non-Executive Director at International Biotech Trust at the time of this trade.
 Jim Horsburgh
421.71GBX5,00015000
25-Jan-16Buy
Trade Notifier Information for International Biotech Trust
Caroline Gulliver held the position of Non-Executive Director at International Biotech Trust at the time of this trade.
 Caroline Gulliver
468GBX2,5005000
26-Aug-15Buy
Trade Notifier Information for International Biotech Trust
Veronique Bouchet held the position of Non-Executive Director at International Biotech Trust at the time of this trade.
 Veronique Bouchet
493.5GBX2,5007500
View more Int.biotech. directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
3 Jan '18TimeNotTimingWell Done618.00No Opinion
Well done forgiving info on this board Sheepy. Good luck and best wishes for the future.
1 Nov '17Sheepy57No subject605.00No Opinion
I'm out. Don't see it going up as fast as I expected so it's time to say goodbye. Will try somewhere else.
2 Oct '17Sheepy57GILD got its mojo back618.00No Opinion
Don't give up on GILD stock yet -- go long for free
By Nicolas Chahine, InvestorPlace Contributor | Sep 29, 2017, 9:59 am EDT
Gilead Sciences, Inc. (NASDAQ:GILD) stock suffered a nasty 50% correction from its $123 per share high. It finally found footing in June of this year. The slide started mid 2015 and the stock set a lower high and the lower low until it was finally able to stabilize around $64.00 per share. And therein lies my opportunity.

GILD Stock: Gilead Sciences, Inc. (GILD)… Read More
7 Sep '17Sheepy57Biotechnology bonanza627.75No Opinion
19 Jul '17Sheepy57Vertex report621.00No Opinion
Vertex Pharmaceuticals Inc. on Tuesday released clinical findings showing its new approach to combating cystic fibrosis substantially improved lung function in patients, lifting hopes for a treatment that could be used by about 68,000 people worldwide — including 24,000 who don’t respond to any existing medicines.

The results prompted Boston-based Vertex to say it plans to launch one or two late-stage clinical trials of the biotech’s three-drug combination in the first half… Read More
13 Jul '17Sheepy57Biotech Q217: it's mostly all gravy606.00No Opinion
http://www.barrons.com/articles/biotech-2q17-its-mostly-all-gravy-1499953599
"SunTrust Robinson Humphrey's biotechnology team expects Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Celgene (CELG), Clovis Oncology (CLVS), Incyte (INCY), Sarepta Pharmaceutical (SRPT), and Tesaro (TSRO) to beat consensus revenue estimates. Regeneron (REGN) and Seattle Genetics (SGEN), on the other hand, "are likely to report in-line results."
Another rosy prediction for the… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Int.biotech. (IBT) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.